Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.

Nobis M, McGhee EJ, Morton JP, Schwarz JP, Karim SA, Quinn J, Edward M, Campbell AD, McGarry LC, Evans TR, Brunton VG, Frame MC, Carragher NO, Wang Y, Sansom OJ, Timpson P, Anderson KI.

Cancer Res. 2013 Aug 1;73(15):4674-86. doi: 10.1158/0008-5472.CAN-12-4545. Epub 2013 Jun 7.

2.

Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging.

Nobis M, McGhee EJ, Herrmann D, Magenau A, Morton JP, Anderson KI, Timpson P.

Cell Adh Migr. 2014;8(5):478-86. doi: 10.4161/19336918.2014.970004.

3.

Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M, Olson MF, Frame MC, Brunton VG, Sansom OJ, Anderson KI.

Cancer Res. 2011 Feb 1;71(3):747-57. doi: 10.1158/0008-5472.CAN-10-2267. Epub 2011 Jan 25.

4.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.

PMID:
23616343
5.

The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.

Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, Southall SM, Wilson JR, Erler JT.

J Natl Cancer Inst. 2011 Mar 2;103(5):407-24. doi: 10.1093/jnci/djq569. Epub 2011 Jan 31.

6.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

7.

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27.

PMID:
18301894
8.

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.

Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG.

Gastroenterology. 2010 Jul;139(1):292-303. doi: 10.1053/j.gastro.2010.03.034. Epub 2010 Mar 17.

PMID:
20303350
9.

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE.

Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14.

10.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
11.

Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.

Dhawan G, Combs CK.

J Neuroinflammation. 2012 Jul 2;9:117. doi: 10.1186/1742-2094-9-117.

12.

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.

Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE.

Cancer Res. 2008 May 1;68(9):3323-33. doi: 10.1158/0008-5472.CAN-07-2997.

13.

Parallelized TCSPC for dynamic intravital fluorescence lifetime imaging: quantifying neuronal dysfunction in neuroinflammation.

Rinnenthal JL, Börnchen C, Radbruch H, Andresen V, Mossakowski A, Siffrin V, Seelemann T, Spiecker H, Moll I, Herz J, Hauser AE, Zipp F, Behne MJ, Niesner R.

PLoS One. 2013 Apr 16;8(4):e60100. doi: 10.1371/journal.pone.0060100. Print 2013.

14.

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Araujo J, Logothetis C.

Cancer Treat Rev. 2010 Oct;36(6):492-500. doi: 10.1016/j.ctrv.2010.02.015. Epub 2010 Mar 11. Review.

15.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

16.

Application of a fluorescence resonance energy transfer (FRET)-based biosensor for detection of drug-induced apoptosis in a 3D breast tumor model.

Anand P, Fu A, Teoh SH, Luo KQ.

Biotechnol Bioeng. 2015 Aug;112(8):1673-82. doi: 10.1002/bit.25572. Epub 2015 Jun 15.

PMID:
25728592
17.

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.

Rice L, Lepler S, Pampo C, Siemann DW.

Clin Exp Metastasis. 2012 Feb;29(2):133-42. doi: 10.1007/s10585-011-9436-2. Epub 2011 Dec 1.

PMID:
22130962
19.

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.

Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21.

20.

Significance of ER-Src axis in hormonal therapy resistance.

Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR, Vadlamudi RK.

Breast Cancer Res Treat. 2011 Nov;130(2):377-85. doi: 10.1007/s10549-010-1312-2. Epub 2010 Dec 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk